Лущик А. Я., Гилеп А. А., Грабовец И. П., Усанов С. А. Гетерологическая экспрессия, выделение и физико-химические свойства рекомбинантного цитохрома CYP1B1 человека. Известия Национальной академии наук Беларуси. Серия химических наук. 2015;(1):79-84.
1. Guengerich F. P. Cytochromes P450, drugs, and diseases. Mol Interv, 2003. Vol. 3, N 4. P. 194-204.
2. Hodgson J. ADMET-turning chemicals into drugs. Nat Biotechnol, 2001. Vol. 19, N 8. P. 722-726.
3. Stoilov I. et al. Sequence analysis and homology modeling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am J Hum Genet,1998. Vol. 62, N 3. P. 573-584.
4. Shehin S. E., Stephenson R. O., Greenlee W. F. Transcriptional regulation of the human CYP1B1 gene. Evidence for involvement of an aryl hydrocarbon receptor response element in constitutive expression. J Biol Chem, 2000. Vol. 275, N 10. P. 6770-6776.
5. Shimada T. et al. Arylhydrocarbon receptor-dependent induction of liver and lung cytochromes P450 1A1, 1A2, and1B1 by polycyclic aromatic hydrocarbons and polychlorinated biphenyls in genetically engineered C57BL/6J mice. Carcinogenesis, 2002. Vol. 23, N 7. P. 1199-1207.
6. Beedanagari S. R., Taylor R. T., Hankinson O. Differential regulation of the dioxin-induced Cyp1a1 and Cyp1b1 genes in mouse hepatoma and fibroblast cell lines. Toxicol Lett. Vol. 194, N 1-2. P. 26-33.
7. Nelson D. R. et al. P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics, 1996. Vol. 6, N 1. P. 1-42.
8. Hanna I. H. et al. Cytochrome P450 1B1 (CYP1B1) pharmacogenetics: association of polymorphisms with functional differences in estrogen hydroxylation activity. Cancer Res, 2000. Vol. 60, N 13. P. 3440-3444.
9. McFadyen M. C. et al. Cytochrome P450 CYP1B1 protein expression: a novel mechanism of anticancer drug resistance. Biochem Pharmacol, 2001. Vol. 62, N 2. P. 207-212.
10. Sasaki M. et al. Polymorphisms of the CYP1B1 gene as risk factors for human renal cell cancer. Clin Cancer Res,2004. Vol. 10, N 6. P. 2015-2019.
11. Chaib H. et al. Profiling and verification of gene expression patterns in normal and malignant human prostate tissues by cDNA microarray analysis. Neoplasia, 2001. Vol. 3, N 1. P. 43-52.
12. Bhattacharjee A. et al. Leu432Val polymorphism in CYP1B1 as a susceptible factor towards predisposition to primary open-angle glaucoma. Mol Vis, 2008. Vol. 14. P. 841-850.
13. Stoilov I., Akarsu A. N., Sarfarazi M. Identification of three different truncating mutations in cytochrome P4501B1 (CYP1B1) as the principal cause of primary congenital glaucoma (Buphthalmos) in families linked to the GLC3A locus on chromosome 2p21. Hum Mol Genet, 1997. Vol. 6, N 4. P. 641-647.
14. Guengerich F. P. et al. Heterologous expression of human drug-metabolizing enzymes. Drug Metab Dispos, 1997. Vol. 25, N 11. P. 1234-1241.
15. Strushkevich N. et al. Structural analysis of CYP2R1 in complex with vitamin D3. J Mol Biol, 2008. Vol. 380, N 1. P. 95-106.
16. Mookherjee S. et al. Molecular basis for involvement of CYP1B1 in MYOC upregulation and its potential implication in glaucoma pathogenesis. PLoS One, 2012. Vol. 7, N 9. P. e45077.
17. Chambers D. et al. RALDH-independent generation of retinoic acid during vertebrate embryogenesis by CYP1B1. Development, 2007. Vol. 134, N 7. P. 1369-1383.
